SCHEMBL12424698

SCHEMBL12424698

COc1ccc2c3c(cc(O)c2c1)C1(CC(C)(C)CC(C)(C)C1)c1ccccc1-c1ccccc1-3

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 5/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
GAA P10253 1/20 0.37
HSP90AA1 P07900 2/20 0.34
HDAC4 P56524 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
CCNB2 O95067 1/20 0.33
CDK1 P06493 1/20 0.33
CCNB1 P14635 1/20 0.33
GSK3A P49840 1/20 0.33
GSK3B P49841 1/20 0.33
CDK5 Q00535 1/20 0.33
CDK5R1 Q15078 1/20 0.33
CCNB3 Q8WWL7 1/20 0.33
PARP1 P09874 2/20 0.32
AR P10275 2/20 0.31
HIF1A Q16665 1/20 0.30
EPAS1 Q99814 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16360204 0.95 MEN1 (0.38) PDK2MEN1KMT2AGAAHSP90AA1
SCHEMBL12509870 0.87 PDK2 (0.33) PDK2MEN1KMT2AGAAHSP90AA1
SCHEMBL12424702 0.86 PARP1 (0.35) PDK2MEN1KMT2AGAAPARP1
SCHEMBL22005185 0.86 MEN1 (0.34) PDK2MEN1KMT2AGAA
SCHEMBL13868655 0.84 PDK2 (0.34) PDK2MEN1KMT2AGAAHSP90AA1
SCHEMBL10293306 0.84 PDK2 (0.34) PDK2MEN1KMT2AGAAHSP90AA1
SCHEMBL10261681 0.84 PDK2 (0.34) PDK2MEN1KMT2AGAAHSP90AA1
SCHEMBL24404156 0.84 PDK2 (0.35) PDK2MEN1KMT2AGAAPARP1
SCHEMBL12424597 0.83 PDK2 (0.42) PDK2MEN1KMT2AGAAHSP90AA1
SCHEMBL13868641 0.83 HDAC4 (0.40) PDK2MEN1KMT2AGAAHDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7976739-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2011-07-12 US disclosed
EP-2055698-B1 CHROMENE COMPOUND TOKUYAMA CORP (JP) 2011-04-27 EP disclosed
US-20100230649-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2010-09-16 US disclosed
EP-2055698-A1 CHROMENE COMPOUND Tokuyama Corporation (JP) 2009-05-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100230649-A1 CHROMENE COMPOUND CCNT1, RB1, H1-0 PDK2 1053/4885MEN1 576/4885KMT2A 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.